Predicting diseases. Saving lives. Unlocking the future of precision health through real-time AI and multiomics.
Dynamic Multiome
Global scale, early impact, and powerful return
— through AI and multiomics.
Up to 1 billion Quality-Adjusted Life Years (QALYs) saved through earlier, smarter medical intervention.
Accurate 3–18 month forecasting for heart failure, kidney decline, and cancer powered by real-world longitudinal data.
2× larger than the entire SRA database, enabling next-level population analytics.
/ Dynamic Multiomics in shaping the future of healthcare.
/ Dynamic Multiomics in shaping the future of healthcare.
0
+
Over three longitudinal phases, collecting real-time biological data and clinical input.
0
Years
Phased execution including follow-ups, remote check-ins, and sample collection milestones.
0
+ Experts
Guided by experts from Harvard, Yale, MD Anderson, and leading global institutions.
- cfDNA methylation (plasma)
- Extracellular vesicle RNA
- PBMC single-cell RNAseq
- Standardized blood collection protocol
- Sampling across 4 timepoints (0, 1, 3, 6 months) in Phase 1
- 12-month and telemedicine check-ins in Phase 2
- Potential Phase 3 extension to 5+ years
- Synthesis of specialized compounds and reagents
- Tailored solutions for specific research needs
- Advanced data analysis services
- Comprehensive interpretation and reporting
